NIAID provides resources to support product development at each stage of the pipeline.
Basic research resources include the distribution of viral isolates and reagents through the NIAID-funded BEI Resources Repository. BEI recently posted information specific to 2019-nCoV. NIAID also provides structural and genomic data through its resources made available through public databases. Information on 2019-nCoV is available through a NIAID-funded Bioinformatics Resource Center.
In addition to basic research resources, NIAID maintains a comprehensive suite of preclinical services for the scientific community. These include in vitro and in vivo screening, assay development, product optimization, safety and toxicology testing, and GMP manufacturing. Note that the purpose of these NIAID services is not to assist researchers in developing a particular product from start to finish, but rather to lower the financial risk to product developers by providing limited, but critical, information to fill specific gaps in the product development pipeline. NIAID is working to expand its preclinical services to add assays for testing candidate products against the 2019 nCoV in vitro and in animal models once these assays are available.
Finally, NIAID has clinical networks to evaluate promising products in clinical trials. These include the Infectious Diseases Clinical Research Consortium (IDCRC), which encompasses the long-standing NIAID Vaccine and Treatment Evaluation Units (VTEU), and the Phase 1 Clinical Trial Units for Therapeutics.
More information on coronavirus resources available to the scientific community.